Will Fiddaman earn enough for a trip to Oz with his paid for advertising from CCHR / Scientology

More paid for advertising from CCHR / Scientology - perhaps Bob will earn enough for a trip to Oz

click image to enlarge

Bob Fiddaman & Scientology linked - interest this time from New York

ISP EARTHLINK INC


Domain MINDSPRING.COM

City NEW YORK

Region NEW YORK

Country UNITED STATES

Returning Visits 0

Date Time WebPage

September 22, 2009 2:22:10 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED

http://bobfiddaman.blogspot.com/

http://forums.whyweprotest.net/291-scientology-discussion/bob-fiddaman-seroxat-s cientology-53313/

MISSOURI USA - more interest in the Bob Fiddaman Scientology links

ISP CHARTER COMMUNICATIONS


Domain CHARTER.COM

City WENTZVILLE

Region MISSOURI

Country UNITED STATES

Returning Visits 3

Date Time WebPage

September 22, 2009 3:58:36 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED

http://bobfiddaman.blogspot.com/search?updated-max=2009-09-07T09%3A49%3A00%2B01%3A00 &max-results=12

http://bobfiddaman.blogspot.com/search?updated-max=2009-09-15T08%3A38%3A00%2B01% 3A00&max-results=12

September 22, 2009 1:44:15 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED

http://bobfiddaman.blogspot.com/search?updated-max=2009-09-15T08%3A38%3A00%2B01%3A00 &max-results=12

http://bobfiddaman.blogspot.com/

September 22, 2009 1:44:04 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED

http://bobfiddaman.blogspot.com/

Referrer link not available

September 22, 2009 1:44:01 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED

http://bobfiddaman.blogspot.com/

http://forums.whyweprotest.net/291-scientology-discussion/bob-fiddaman-seroxat-s cientology-53313

Calgary, Alberta - visitors interested in the Scientology Bob Fiddaman connection

ISP SHAW COMMUNICATIONS INC


Domain SHAWCABLE.NET

City CALGARY

Region ALBERTA

Country CANADA

Returning Visits 4

Date Time WebPage

September 22, 2009 4:01:23 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED

http://bobfiddaman.blogspot.com/

http://forums.whyweprotest.net/291-scientology-discussion/bob-fiddaman-seroxat-s cientology-53313/

September 22, 2009 4:00:46 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED

http://bobfiddaman.blogspot.com/

http://forums.whyweprotest.net/291-scientology-discussion/bob-fiddaman-seroxat-s cientology-53313/

Health information sources frequently quoted by Fiddaman are all Scientology fronts

Mental Health Alternatives « CCHR International: "HEALTH OPTIONS & INFORMATION
Naturalnews.com — Independent News on Natural Health, Nutrition and More
http://www.naturalnews.com
Natural Solutions — Natural Remedies & Healthy Solutions
http://www.naturalsolutionsmag.com
AbleChild
http://www.ablechild.org
Natural Health Education
http://www.thepeopleschemist.com"

Scientology sponsors Fiddaman Seroxat Blog

Click image to enlarge - Fiddaman blog bought by Scientology !

CCHR International - links to their lawyers

Mental Health Alternatives « CCHR International: "LEGAL RESOURCES
Bailey Perrin Bailey — Large Civil Litigation Firm Specializing in Personal Injury Litigation
http://www.bpblaw.com
Baum, Hedlund, Aristei & Goldman — Wrongful Death and Personal Injury Lawyers
http://www.baumhedlundlaw.com
Vickery Waldner & Mallia LLP — Wrongful Death and Medical Negligence Lawyers
http://www.justiceseekers.com
Weitz & Luxenberg P.C. — Personal Injury and Medical Malpractice Lawyers
http://www.weitzlux.com"

Judge orders Glaxo to provide emails between it and researchers regarding Paxil-birth defect connection. « CCHR International

Judge orders Glaxo to provide emails between it and researchers regarding Paxil-birth defect connection. « CCHR International: "Judge Says Glaxo Must Turn Over Paxil Emails"

On trial – Did drug giant GlaxoSmithKline know Paxil could cause birth defects more than 20 years ago? « CCHR International

On trial – Did drug giant GlaxoSmithKline know Paxil could cause birth defects more than 20 years ago? « CCHR International: "Glaxo Executive’s Memo Suggested Burying Drug Studies"

they can hide behind a proxy - but Mark Harvey can't deny the issuing of a death threat

Host Name 42ob.scansafe.net


IP Address 80.254.147.20

ISP LON2-ITR

Domain -

City -

Region -

Country UNITED KINGDOM

Returning Visits 0

Date Time WebPage

September 17, 2009 4:43:33 PM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Seroxat solicitor Mark Harvey does not deny the issuing of a death threat

http://bobfiddaman.blogspot.com/2009/07/blog-post_6657.html

http://www.google.co.uk/search?hl=en&source=hp&q=mark harvey solicitor&meta=&aq= 2&oq=mark harvey

September 17, 2009 4:42:59 PM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Seroxat solicitor Mark Harvey does not deny the issuing of a death threat

http://bobfiddaman.blogspot.com/2009/07/blog-post_6657.html

http://www.google.co.uk/search?hl=en&source=hp&q=mark harvey solicitor&meta=&aq= 2&oq=mark harvey

UNIVERSITY OF IOANNINA - checking out Bob Fiddaman & his connections to Scientology

ISP UNIVERSITY OF IOANNINA


Domain UOI.GR

City -

Region -

Country GREECE

Returning Visits 0

Date Time WebPage

September 18, 2009 9:45:01 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: CCHR / Scientology pay for Fiddaman's anti GSK ranting - 23 July 2009

http://bobfiddaman.blogspot.com/2009/07/blog-post_24.html

http://www.google.gr/search?hl=el&source=hp&q=cchr seroxat&meta=&aq=f&oq=cchr se roxa

September 18, 2009 9:44:27 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: CCHR / Scientology pay for Fiddaman's anti GSK ranting - 23 July 2009

http://bobfiddaman.blogspot.com/2009/07/blog-post_24.html

http://www.google.gr/search?hl=el&source=hp&q=cchr seroxat&meta=&aq=f&oq=cchr se roxa

September 18, 2009 9:43:39 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: CCHR / Scientology pay for Fiddaman's anti GSK ranting - 23 July 2009

http://bobfiddaman.blogspot.com/2009/07/blog-post_24.html

http://www.google.gr/search?hl=el&source=hp&q=cchr seroxat&meta=&aq=f&oq=cchr se roxa

September 18, 2009 9:42:18 AM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: CCHR / Scientology pay for Fiddaman's anti GSK ranting - 23 July 2009

http://bobfiddaman.blogspot.com/2009/07/blog-post_24.html

http://www.google.gr/search?hl=el&source=hp&q=cchr seroxat

Recent visitor - UNIVERSITY OF WALES BANGOR - David Healy Meeting at MHRA

ISP UNIVERSITY OF WALES BANGOR


Domain BANGOR.AC.UK

City -

Region -

Country UNITED KINGDOM

Returning Visits 9

Date Time WebPage

September 17, 2009 1:45:47 PM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: MHRA - Dr DAVID HEALY MEETING

http://bobfiddaman.blogspot.com/2009/08/mhra-dr-david-healy-meeting.html

Referrer link not available

September 17, 2009 1:45:43 PM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: MHRA - Dr DAVID HEALY MEETING

http://bobfiddaman.blogspot.com/2009/08/mhra-dr-david-healy-meeting.html

Referrer link not available

September 17, 2009 1:45:27 PM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: MHRA - Dr DAVID HEALY MEETING

http://bobfiddaman.blogspot.com/2009/08/mhra-dr-david-healy-meeting.html

http://www.google.co.uk/search?hl=en&source=hp&q=david healy gsk&btnG=Google Sea rch&meta=&aq=f&oq=

Solicitor abused position to campaign against cutbacks

Solicitor abused position to campaign against cutbacks

http://www.telegraph.co.uk/news/uknews/6189064/Solicitor-abused-position-to-campaign-against-cutbacks.html


A solicitor who made her name helping people fight against closures of care homes abused her position by encouraging clients to protest against cut services, a tribunal has heard.



By Chris Irvine

Published: 5:05PM BST 14 Sep 2009



Yvonne Hossack allegedly breached rules of solicitors' conduct by writing to clients, those living in care homes or their families, inappropriately encouraging them to get involved in a media campaign. The Solicitors Disciplinary Tribunal was told that she breached client confidentiality and carried out instructions on clients' behalf without their consent.



Jonathan Goodwin, for the Solicitors' Regulation Authority, told the hearing in central London: "This case is not about whether Miss Hossack is a caring individual. It is evident that she cares.





Related Articles

Solicitor faces being struck off after fighting councils' care cuts



The issue in the case is whether the way in which she has conducted herself in certain identified respects was appropriate or not, and we submit that the conduct was not appropriate and she breached certain rules of conduct."



Mr Goodwin said that Miss Hossack, 53, from Kettering, "stepped outside the role of legal adviser" when she encouragd a media and political campaign.



She also went "off on frolics of her own" by launching legal action without instructions from client, the Tribunal was told.



The hearing was prompted because councils in Northamptonshire, Staffordshire and Hull complained to the Law Society about Miss Hossack, alleging that she forced them waste time and money in court.



Mr Hossack claims to have saved at least 80 care homes from closure thanks to her previous work.



She is accused of six breaches of rules governing solicitors' conduct, including accepting instructions from third parties without seeking clarification of the position and providing confidential information to third parties. If she is found to have breached the rules she could be fined, suspended or kicked out of the legal profession altogether.



Mr Goodwin claimed she had breached the confidentiality of eight clients following a letter to the General Medical Council complaining about a doctor.



Although he said she admitted to doing so "in the utmost good faith", Mr Goodwin said: "The fundamental principle of client confidentiality should have prevented her from making a complaint to the GMC in the way she did."



He added: "Whether or not it's the right thing to do, a solicitor requires instructions and she should not have disclosed the confidential information."



Miss Hossack, representing herself, later accused a witness, Dr Peter Jefferys of Northwick Park Hospital in Harrow, of being "dangerous and corrupt" when cross-examining him.



Dr Jefferys later said the GMC had written to him saying the case that Miss Hossack was referring to did not warrant further investigation.



When questioning Dr Jefferys, about alleged inconsistencies in reports he had written, she told panel chairman Dominic Green, "I did not reveal confidential information to the GMC lightly."



She told the tribunal: "I get the feeling that you are here to end my career and ruin my reputation to protect this man."



Mr Green replied: "We are independent of the Law Society and the Solicitors' Regulation Authority and we will make sure you have your say."



Miss Hossack denies all counts against her.



The hearing continues.

NEWS - it's a "potent and irreversible inactivator of CYP2D6 (cytochrome P450 2D6), a key liver enzyme" IRREVERSIBLE

Paroxetine


has been shown to be an effective treatment for VMS. However, it is a potent and


irreversible inactivator of CYP2D6 (cytochrome P450 2D6), a key liver enzyme


responsible for the metabolism of many commonly-prescribed drugs.

http://www.reuters.com/article/pressRelease/idUS93196+14-Sep-2009+BW20090914

News - Deuterium-Modified Seroxat / Paxil / Paroxetine

http://www.reuters.com/article/pressRelease/idUS93196+14-Sep-2009+BW20090914

Phase I Results Presented at American College of Clinical Pharmacology


SAN ANTONIO--(Business Wire)--

Concert Pharmaceuticals, Inc. announced today the presentation of Phase 1 data

on CTP-347, a deuterium-modified analog of paroxetine for the treatment of hot

flashes. Concert presented the results during a poster session at the American

College of Clinical Pharmacology`s 38th Annual Meeting. This presentation

highlighted that subjects treated with CTP-347 substantially retained cytochrome

P450 2D6 (CYP2D6) enzyme activity. This enzyme is necessary for the metabolism

of many common drugs, but is irreversibly inactivated by a metabolite of

paroxetine, causing significant drug-drug interactions. Concert believes these

findings represent the first reported clinical data demonstrating that deuterium

substitution can alter a drug`s metabolism to reduce the potential for drug-drug

interactions in humans.



"This proof-of-concept study, combined with our preclinical findings,

demonstrates how we can apply deuterium chemistry to a proven drug to suppress

formation of an undesirable metabolite, while retaining the drug`s beneficial

pharmacologic activity," said Roger Tung, Ph.D., President and Chief Executive

Officer. "These are exciting results and provide one example of how our

deuterium chemistry platform can leverage proven drugs to create highly

differentiated yet risk-reduced new medicines."



The Phase 1 clinical trial was a randomized, single-blind, placebo-controlled,

ascending single- and multiple-dose study in 94 healthy volunteers. The primary

objective of the study was to evaluate the safety, tolerability and

pharmacokinetics of CTP-347. In this trial, CTP-347 was well-tolerated at all

doses evaluated and there were no clinically significant adverse events

reported. The most common adverse events were typical of selective serotonin

reuptake inhibitors (SSRIs) including headache, nausea and dizziness. In vitro

studies have previously shown that CTP-347, unlike paroxetine, does not exhibit

mechanism-based inactivation of CYP2D6 in human liver microsomes. The

pharmacokinetics of CTP-347 were consistent with those observed in preclinical

studies.



CTP-347 is a new chemical entity developed from Concert`s deuterium chemistry

platform by replacing key hydrogen atoms of paroxetine with deuterium as a

non-hormonal treatment for vasomotor symptoms (VMS) or hot flashes. Paroxetine

has been shown to be an effective treatment for VMS. However, it is a potent and

irreversible inactivator of CYP2D6 (cytochrome P450 2D6), a key liver enzyme

responsible for the metabolism of many commonly-prescribed drugs. Currently,

there is no FDA-approved non-hormonal treatment for VMS, a serious and sometimes

long-term condition associated with a range of undesirable effects including

depression, insomnia and lost productivity. Hormone replacement therapy can

effectively treat VMS. However, patients who currently or previously have been

treated for cancers of the breast or ovary, or who have a familial history of

these cancers, are often advised to avoid hormonal treatment. A non-hormonal

therapy may also be preferred by women who experience VMS following menopause in

whom hormone therapy is contraindicated or who have concerns about long-term

health risks posed by hormone replacement therapy.



About Deuterium



Deuterium is a safe, non-radioactive relative of hydrogen that can be isolated

from sea water and has been used extensively in human metabolic and clinical

studies. Since deuterium resembles hydrogen, deuterium-containing compounds are

expected to preserve the pharmacological activity of their hydrogen analogs. An

important difference is that deuterium is heavier than hydrogen and therefore

forms a stronger chemical bond to a carbon atom of a drug. The stronger chemical

bond obtained by selective deuterium modification in select instances may

substantially improve the drug`s metabolic properties, potentially resulting in

better safety, tolerability and/or efficacy.



About Concert



Concert Pharmaceuticals is a clinical stage biotechnology company focused on the

application of deuterium chemistry to create novel small molecule drugs.

Concert`s approach leverages known activity and safety of existing drugs to

reduce time, risk and expense of drug research and development. The Company has

a broad research pipeline encompassing many therapeutic areas including

infectious disease and renal disease, among others. Its lead development

candidate is the HIV protease inhibitor CTP-518. In 2009, Concert entered into a

potential $1 billion collaboration with GlaxoSmithKline to develop certain

deuterium-containing medicines. Founded in 2006, Concert has raised more than

$110 million of venture and institutional capital. For more information on

Concert Pharmaceuticals, please visit www.concertpharma.com.

SSRI DISCUSSION FORUM: "Women given antidepressant that can cause birth defects"

SSRI DISCUSSION FORUM: "Women given antidepressant that can cause birth defects": "All SSRIs pose a risk, said Healy. The danger with recent warnings from the FDA and MHRA about Seroxat is that GPs will switch women to another drug of the same class."

"...All SSRIs pose a risk, said Healy. The danger with recent warnings from the FDA and MHRA about Seroxat is that GPs will switch women to another drug of the same class...."

"...All SSRIs pose a risk, said Healy. The danger with recent warnings from the FDA and MHRA about Seroxat is that GPs will switch women to another drug of the same class...."








A point that the UK media usually (at times shamefully) fail to include.



That ALL SSRIs pose a risk to unborn babies, newborns, and pregnant women.



http://www.antidepressantsfacts.com/safe.htm





2004

10/03

Washingt.Post Nobody really knows what SSRI's do in the brain (2)



2004

09/00

Case/Study Baby toxicity: Prozac persisted in cord & maternal serum



2004

08/09

WARNING Health Canada: Neurological Effects SSRI's on Newborns



2004

08/00

Case/Study SSRI's during pregnancy: Damaging Effects on the Fetus



2004

06/00

Case/Review SSRI's & Babies: agitation, breathing & suction problems



2004

02/00

Case/Study SSRI's and Pregnancy: Foetal Brain Damage, disruptions



2004

02/23

The Age Study links antidepressants to Foetal Brain Damage



2003

11/00

Case/Review Baby Haemorrhage with maternal use of Paxil/Seroxat









Pregnancy and Baby Caution







2003

10/12

AHRP.com Prozac/Sarafem no longer authorized for use in PMDD



2003

08/00

Case/Review Newborns & SSRI's: hypoglycaemia, rapid pulse, jaundice



2003

08/04

SidneyHerald Alert over taking Prozac during pregnancy



2003

07/00

Case/Review Increased risk baby problems with SSRIs in late pregnancy



2003

07/15

Atlan.Journ. Newer Antidepressants Can Harm Newborns



2003

07/14

Case/Review SSRI's in Pregnancy: Neurologic Symptoms in Newborns



2003

07/12

Case/Review Effexor during Pregnancy: Withdrawal side-effects in Baby



2003

04/16

Case/Review Paxil during Pregnancy: Neonatal Seizures & Hemorrhage



2002

03/05

Case/Review Male Breast Cancer (neoplasia) in association with SSRI's



2001

00/00

Drug Safety Neonatal AntiDepressant Discontinuation Syndromes



2001

09/00

Case/Review Paxil in Pregnancy: Baby Serotonin/Withdrawal Syndrome



2001

03/00

Case/Review Neonatal Withdrawal Syndrome after in utero exposure to SSRI's



2001

03/00

Case/Review BABY SSRI withdrawal lasting up to one month after birth



2001

03/00

Case/Review BABY Withdrawal Syndrome after exposure to SSRI's



2001

01/01

J.Psych&Neur. SSRI-AntiDepressants and Pregnancy



2000

10/11

Case/Review Prozac Toxicity in preterm infant: neurological symptoms & skin manifestations



1999

11/00

Case/Study Breastfeeding while taking Prozac associated with reduced growth infants



1997

11/00

Case/Review SSRI's, Breast Milk and Baby Withdrawal Symptoms



1996

11/05

MedicalPost Row Erupts over Use of Prozac in Pregnancy

1996

10/02

CNN Health Prozac may effect Baby -link Prozac & premature births

Welcome to visitor BBC - hope you enjoy the Shelley Jofre podcast?

Label Visitor
Host Name webgw2.thls.bbc.co.uk
IP Address 132.185.240.122
ISP BRITISH BROADCASTING CORPORATION
Domain BBC.CO.UK
City LONDON
Region ENGLAND
Country UNITED KINGDOM
Returning Visits 0
Date Time WebPage
September 14, 2009 12:29:44 PM SEROXAT SUFFERERS - STAND UP AND BE COUNTED: 22-Aug-2009
http://bobfiddaman.blogspot.com/2009_08_22_archive.html

Furious Seasons - "Brother, Can You Spare a Dime?",

I'd like to think that every so often I'm worth the price of the Sunday Times or whatever magazines you read. That's why I'd like to ask all you regular readers out there--and that's about 5,000 people--to make a large number of small contributions. If that happens, this fundraiser will succeed. If it doesn't, I'm going to have to scale back dramatically in the work I do here and go do something else with my time.

http://www.furiousseasons.com/